BioAgilytix to be Acquired by Private Investment Company Cobepa

Acquisition Will Provide BioAgilytix with Additional Resources to Support Customers’ Growing Large Molecule Bioanalytical Demands with High-Quality Services

November 2, 2018—Durham, NC, USA and Brussels, Belgium—BioAgilytix, a leading provider of large molecule bioanalytical testing services, today announced an agreement to be acquired by Cobepa S.A., a privately-held investment company. Riverside Partners, a Boston-based private equity firm, originally acquired BioAgilytix in 2013 and has built the company into a recognized global leader in large molecule bioanalysis. The acquisition by Cobepa will provide BioAgilytix with increased funding and resources to meet growing demand for its high-quality services, driven by its strong scientific reputation and leading expertise in biologics development.

“We have built a team with an excellent reputation for quality science and superior service, which has allowed us to expand our work with existing customers and grow our customer base significantly over the past several years,” said Jim Datin, President and CEO of BioAgilytix. “Going forward, Cobepa will provide additional capital as well as access to their broad international network, which will empower us to continue serving our clients’ evolving and expanding bioanalytical needs. It will enable us to invest in further building out our talented team, expanding our advanced lab facilities in both the USA and Europe, and adding adjacent bioanalytical services that will benefit our customers.”

“It has been extremely fulfilling to partner with BioAgilytix and help the company grow into the world-class organization it is today,” said David Belluck, General Partner, Riverside Partners. “BioAgilytix’s success is a testament to the commitment of its management team and employees to solving their customers’ unique scientific challenges. We are proud to have supported the company by significantly growing the scientific organization, meaningfully expanding laboratory capacity, broadening the customer base, completing the acquisition of Hamburg-based IPM Biotech, and implementing best-in-class systems and processes.”

“We recognize BioAgilytix as a leader in the specialty area of large molecule bioanalysis, and with our support, its team will be fully equipped to help global pharmaceutical and biotech sponsors bring more large molecule drugs to market, faster,” said Peter Connolly, Managing Director, Cobepa North America. “We are pleased to partner with BioAgilytix in the next phase of its development, providing the resources necessary to extend its impressive track record, retain and add to its respected team, and solidify its position as the premier worldwide provider of large molecule bioanalytical testing services.”

The transaction, which is subject to customary closing conditions and regulatory approvals, is expected to close later this month.

Wells Fargo Securities, LLC is acting as lead financial advisor to BioAgilytix. Lincoln International, LLC is also serving as a financial advisor to the company. Choate Hall & Stewart LLP is serving as legal counsel to BioAgilytix.


About BioAgilytix

BioAgilytix is a leading bioanalytical testing laboratory specializing in large molecule bioanalysis. With laboratory locations in North Carolina’s Research Triangle area and Hamburg, Germany, BioAgilytix provides PK, immunogenicity, biomarkers, and cell-based assay services supporting the development and release testing of biologics across a number of industries and disease states. BioAgilytix offers assay development, validation, and sample analysis under non-GLP, GLP, and GCP, as well as GMP quality control testing (i.e. product release testing, stability testing, etc.).

BioAgilytix’s team of highly experienced scientific and QA professionals ensures high quality science, data integrity, and regulatory compliance through all phases of clinical development, and is a trusted partner to many of the top global pharmaceutical and biotech companies. For more information, visit

About Cobepa

Based in Brussels and New York, Cobepa is a privately-held investment company backed by European families. Cobepa manages a diversified portfolio of private equity investments valued at around €2.5 billion. Cobepa invests in leading companies with strong business models, sustainable market positions and strong management teams. For more information, visit

Media Contact:
Jennifer Absher
(919) 287-1573
[email protected]

Featured Expert

Pharmacokinetics & Pharmacodynamics​

See how our PK expertise complements our immunogenicity services by evaluating absorption, distribution, metabolism and excretion characteristics of a product.
220328 Adleverage_Scientific Icon Illustrations_#46-65_CO_Per FIles